	US 11,851,470 B2
	Platforms, compositions, and methods for therapeutic delivery
Milad Riazifar, Irvine, CA (US); Charles Cameron Taylor, Long Beach, CA (US); and Todd Schurr, Long Beach, CA (US)
Assigned to Entelexo Biotherapeutics, Inc., Irvine, CA (US)
Filed by Entelexo Biotherapeutics, Inc., Irvine, CA (US)
Filed on Jun. 30, 2022, as Appl. No. 17/855,305.
Application 17/855,305 is a continuation of application No. 17/556,572, filed on Dec. 20, 2021.
Application 17/556,572 is a continuation of application No. PCT/US2020/038816, filed on Jun. 19, 2020.
Claims priority of provisional application 62/875,001, filed on Jul. 17, 2019.
Claims priority of provisional application 62/864,566, filed on Jun. 21, 2019.
Prior Publication US 2022/0389078 A1, Dec. 8, 2022
Int. Cl. C07K 14/70 (2006.01); A61P 29/00 (2006.01); A61K 9/50 (2006.01); C07K 14/705 (2006.01); A61K 47/42 (2017.01); A61K 38/00 (2006.01)

CPC C07K 14/70521 (2013.01) [A61K 9/5068 (2013.01); A61K 47/42 (2013.01); A61P 29/00 (2018.01); C07K 14/70503 (2013.01); C07K 14/70532 (2013.01); C07K 14/70596 (2013.01); A61K 38/00 (2013.01); C07K 2319/03 (2013.01)]

14 Claims

1. A composition comprising a plurality of extracellular vesicles, wherein an extracellular vesicle of the plurality of extracellular vesicles comprises a first immune checkpoint moiety and a second immune checkpoint moiety,

wherein the first immune checkpoint moiety is CD200 and the second immune checkpoint moiety is an extracellular domain of PD-L1,

said extracellular domain of PD-L1 is linked to a transmembrane moiety of the extracellular vesicle,

said transmembrane moiety is different from said second immune checkpoint moiety, and

wherein the second immune checkpoint moiety is exposed on a surface of said extracellular vesicle.